File No. CT/13/20-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARDCONTROL
ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & FamilyWelfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002
91-11-23216367
Fax No.:91-11-23236973
E-Mail :dci@nic.in

सत्यमेव जयते

File No. CT/20/000013

To,

M/s. AstraZeneca Pharma India Ltd.,
Block No 1, 12th Floor, Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road, Karnataka, (India)-560045.

Sir,

With reference to your application No GCT/CT04/FF/2020/18540 (GCT/13/20) dated 11-02-2020 please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)", Protocol number D5169C00001 Protocol Version 1.0 dated 19/March/2019**under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule8;

(ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the samesite;

(iv) the Central Licencing Authority shall be informed about the approval granted by the

Ethics Committee within a period of fifteen working days of the grant of suchapproval;

(v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for thetrial;

(vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of theserules;

(vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever isearlier;

(viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAMportal;

(ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in ChapterVI;

(xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the saidChapter;

(xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the saidChapter;

(xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinicaltrial;

(xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwisejustified;

(xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

File No. CT/13/20-DCG(I)

(xvi)the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinicaltrial;

(xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinicaltrial.

(xviii) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2020.04.07 17:27:33 +05'30'

(Dr. V.G.Somani)
Drugs Controller General (India)
Central Licensing Authority

File No. CT/13/20-DCG(I)

FORM CT-06
(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s.AstraZeneca Pharma India Ltd., Block No 1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Karnataka, (India)-560045** to conduct clinical trial of the new drug or investigational new drug as per **Protocol number D5169C00001 Protocol Version 1.0 dated 19/March/2019** in the below mentioned clinical trial sites [As perAnnexure].-

2. Details of new drug or investigational new drug and clinical trial site [As perAnnexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act,1940.

Place: New Delhi
Date _____

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2020.04.07 17:27:48 +05'30'

(Dr. V.G.Somani)
Drugs Controller General (India)
Central Licensing Authority

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Osimertinib Film coated tablets
Therapeutic class:	Anticancer
Dosage form:	Tablets

File No. CT/13/20-DCG(I)

Composition:	Osimertinib = 40.0000 milligram (mg) in House Specification Active Osimertinib = 80.0000 milligram (mg) in House Specification Active
Indications:	Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer)

Details of clinical trial site:

Names and address of clinical trial site	Ethics committee details	Name of investigator
Bhaktivedanta Hospital and Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (East), Thane, Maharashtra-401107, India	Bhaktivedanta Hospital Ethics Committee, Bhaktivedanta HEC Office, 6th Floor, Bhaktivedanta Hospital and Research Institute, Srishti Complex, Bhaktivedanta Swami Marg, Mira Road (East), Thane, Maharashtra-401107, India ECR/396/Inst/MH/2013/RR-19	Dr. Nirmal Vivek Raut
Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati-444606, Maharashtra, India	Amravati Ethics Committee, Sujan Surgical Cancer Hospital and Amravati Cancer Foundation, 52/B, Shankar Nagar, Main Road, Amravati-444606, Maharashtra, India ECR/432/Inst/MH/2013/RR-16	Dr. Harwani Arun Thakurdas
Yashoda Hospital, Raj Bhavan Road, Matha Nagar, Somajiguda, Hyderabad-82, Telangana	Institutional Ethics Committee, Yashoda Academy of Medical Education and Research, Yashoda Hospitals, Behind Hari Hara Kala Bhawan, Alexander Road, Secunderabad, Hyderabad, Telangana-500003 ECR/49/Inst/AP/2013/RR-19	Dr. Nikhil S Ghadyalpatil
Artemis Hospital, Medical Oncology Department, Sector-51, Gurugram-122001, Haryana, India	Artemis Health Sciences Institutional Ethics Committee, Artemis Hospital, Sector-51, Gurugram-122001, Haryana, India ECR/53/Inst/HR/2013/RR-19	Dr. Hari Goyal
KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Nehrunagar Belagavi-590010, Karnataka, India	Institutional Ethics Committee, KAHER (Formerly known to be KLE University), NMC Campus, Nehrunagar Belagavi-590010, Karnataka, India ECR/211/Inst/KA/2013/RR-19	Dr. Rohan Bise

File No. CT/13/20-DCG(I)

Aster Medcity, Kuttisahib Road, South Chittoor, Cheranalloor, Kochi-682027	Institutional Ethics Committee, Aster Medcity, Kuttisahib Road, South Chittoor, Cheranalloor, Kochi-682027 ECR/737/KL/2015/RR-18	Dr. Arun Warrier
Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi-110085	Institutional Review Board, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, New Delhi-110085 ECR/10/Inst/DC/2013/RR-19	Dr. Sumit Goyal
Shetty's Hospital, Plot No. 11 & 12, 12th F Main Kaveri Nagar, Kodichikkanahalli, Bommanhalli, Bangalore-560068, Karnataka, India	Shetty's Hospital Ethics Committee, Plot No. 11 & 12, 12th F Main Kaveri Nagar, Kodichikkanahalli, Bommanhalli, Bangalore-560068, Karnataka, India ECR/918/Inst/KA/2017	Dr. Lokesh K N
Manipal Hospital, 98, HAL Airport Road, Bangalore-560017, Karnataka, India	Ethics Committee of Manipal Hospitals, Manipal Hospital, 98, HAL Airport Road, Bangalore-560017, Karnataka, India ECR/34/Inst/KA/2013/RR-19	Dr. Amit Rauthan
Shatabdi Hospital, Mumbai Naka, Suyojit City Center, Opp. Mahamarg Bus Stand, Nashik-422001	Shatabdi Hospital Ethics Committee, Shatabdi Hospital, Suyojit City Center, Opp. Mahamarg Bus Stand, Mumbai Naka, Nashik ECR/498/Inst/MH/2014/RR-17	Dr. Shailesh A. Bondarde
HCG Manavata Cancer Centre, Behind Shivang Auto, Mumbai Naka, Nashik-422002, Maharashtra, India	Manavata Clinical Research Institute Ethics Committee, First Floor, Behind Shivang Auto, Mumbai Naka, Nashik-422002, Maharashtra, India ECR/500/Inst/MH/2013/RR-17	Dr. Shruti Kate
Mahatma Gandhi Cancer Hospital and Research Institute, 1/7 MVP Colony, Visakhapatnam-530017, Andhra Pradesh, India	Mahatma Gandhi Cancer Hospital and Research Institute,Institutional Ethics Committee, 1/7 MVP Colony, Visakhapatnam-530017, Andhra Pradesh, India ECR/529/Inst/AP/2014/RR-17	Dr. Praveena Voonna
Shri Venkateshwara Hospitals, # 27, 29th Main Road, Rashtra Kuvempu Nagara, BTM 2nd Stage, BTM layout, Bengaluru-560076, Karnataka, India	Shri Venkateshwara Hospitals, Ethics Committee, # 27, 29th Main Road, Rashtra Kuvempu Nagara, BTM 2nd Stage, BTM layout, Bengaluru-560076, Karnataka, India ECR/298/Inst/KA/2013/RR-16	Dr. Satheesh C.T`

File No. CT/13/20-DCG(I)

HCG Cancer Centre Sola-Science City Road, Near Sola Bridge, S.G.Highway,Ahmedabad-380060, Gujarat, India	HCG Multi Specialty Ethics Committee, HCG Hospitals Mithakhali, Ellisbridge, Ahmedabad-380006 ECR/92/Inst/GJ/2013/RR-19	Dr. Ashish Kaushal
Tata Medical Centre, 14, MAR (E-W), Newtown, Rajarhat, Kolkata-700156	Institutional Review Board, 14, MAR (E-W), Newtown, Rajarhat, Kolkata-700156 ECR/269/Inst/WB/2013/RR-19	Dr. Bivas Biswas
Deenanath Mangeshkar Hospital and Research Centre, Erandawane, Pune-411004, Maharashtra, India	Institutional Ethics Committee, Deenanath Mangeshkar Hospital and Research Centre, Erandawane, Pune-411004, Maharashtra, India ECR/15/Inst/Maha/2013/RR-19	Dr. Chetan Deshmukh
Prince Aly Khan Hospital, Aga Hall, Nesbit Road, Mazagaon, Mumbai, 400010, Maharashtra, India	Institutional Ethics Committee , Prince Aly Khan Hospital, Aga Hall, Nesbit Road, Mazagaon, Mumbai, 400010, Maharashtra, India ECR/100/Inst/Maha/2013/RR-19	Dr. Gore Adawaita Anant